A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
Authors:
- Peter A. ArgentaPAPeter A. Argenta
- Sajeena G. ThomasSTSajeena G. Thomas
- Patricia L. JudsonPJPatricia L. Judson
- Levi S. DownsLDLevi S. Downs
- Melissa A. GellerMGMelissa A. Geller
- Linda F. CarsonLCLinda F. Carson
- Amy L. JonsonAJAmy L. Jonson
- Rahel GhebreRGRahel Ghebre
- 1 May 2009
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 113 (2) , 205-209
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Estrone sulfatase activity in patients with advanced ovarian cancerGynecologic Oncology, 2009
- Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative studyBreast Cancer Research and Treatment, 2007
- Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive PatientsClinical Cancer Research, 2007
- Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programmeBreast Cancer Research and Treatment, 2007
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Induction of Epithelial Neoplasms in the Ovaries of Guinea Pigs by Estrogenic StimulationGynecologic Oncology, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989